Nuvilex Inc. (NASDAQ:PMCB) Short Interest Down 31.3% in December

Nuvilex Inc. (NASDAQ:PMCB) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totaling 635,629 shares, a drop of 31.3% from the November 30th total of 925,578 shares. Currently, 10.4% of the shares of the company are short sold. Based on an average daily trading volume, of 12,965,578 shares, the short-interest ratio is currently 0.0 days. Based on an average daily trading volume, of 12,965,578 shares, the short-interest ratio is currently 0.0 days. Currently, 10.4% of the shares of the company are short sold.

Nuvilex Stock Performance

PMCB stock traded down $0.00 during trading on Monday, hitting $0.71. 515,329 shares of the company’s stock traded hands, compared to its average volume of 879,225. The stock has a market capitalization of $7.16 million, a price-to-earnings ratio of -0.51 and a beta of 0.07. The business has a fifty day simple moving average of $0.88 and a 200 day simple moving average of $0.96. Nuvilex has a 52 week low of $0.63 and a 52 week high of $1.90.

Nuvilex (NASDAQ:PMCB) last posted its quarterly earnings data on Thursday, December 18th. The company reported ($0.32) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Nuvilex in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.